Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Ischaemic disorders are leading causes of morbidity and mortality worldwide. While the current therapeutic approaches have improved life expectancy and quality of life, they are unable to "cure" ischemic diseases and instate regeneration of damaged tissues. Exosomes are a class of extracellular vesicles with an average size of 100-150 nm, secreted by many cell types and considered a potent factor of cells for paracrine effects. Since exosomes contain multiple bioactive components such as growth factors, molecular intermediates of different intracellular pathways, microRNAs and nucleic acids, they are considered as cell-free therapeutics. Besides, exosomes do not rise cell therapy concerns such as teratoma formation, alloreactivity and thrombotic events. In addition, exosomes are stored and utilized more convenient. Interestingly, exosomes could be an ideal complementary therapeutic tool for ischemic disorders. In this review, we discussed therapeutic functions of exosomes in ischemic disorders including angiogenesis induction through various mechanisms with specific attention to vascular endothelial growth factor pathway. Furthermore, different delivery routes of exosomes and different modification strategies including cell preconditioning, gene modification and bioconjugation, were highlighted. Finally, pre-clinical and clinical investigations in which exosomes were used were discussed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003030PMC
http://dx.doi.org/10.1111/jcmm.17689DOI Listing

Publication Analysis

Top Keywords

ischemic disorders
12
exosomes
9
angiogenesis induction
8
exosomes angiogenesis
4
ischemic
4
induction ischemic
4
disorders
4
disorders ischaemic
4
ischaemic disorders
4
disorders leading
4

Similar Publications

BACKGROUND Gastrointestinal mucormycosis is an underrecognized and underreported fungal infection with a high mortality rate. Diagnosis is often confounded by a non-specific constellation of signs and symptoms. We present a case of neutropenic colitis and ileocecal perforation secondary to gastrointestinal mucormycosis.

View Article and Find Full Text PDF

Terminal Harvest Procedure of a Large Animal Model of Chronic Myocardial Ischemia with Hemodynamic Characterization and Perfusion Analysis.

J Vis Exp

August 2025

Department of Surgery, Division of Cardiothoracic Surgery, Warren Alpert Medical School, Brown University; Cardiovascular Research Center, Rhode Island Hospital.

Reproducibility and research integrity are foundational tenets to scientific discovery, which are produced utilizing well-established, proven principles and protocols. Furthermore, with the ever-increasing prevalence and burden cardiovascular disease (CVD) places on individuals and society at large, it deems essential to cultivate robust and validated model for investigation. Our group utilizes a two-surgery protocol in a swine model that has been progressively refined over the last twenty years, in which we first induce chronic myocardial ischemia by placement of an ameroid constrictor mimicking the pathophysiology of coronary artery disease (CAD) in humans.

View Article and Find Full Text PDF

Myocardial ischemia-reperfusion injury (MIRI) endures as a substantial impediment to the management of cardiovascular disease. The pathophysiology of MIRI is complex, involving oxidative stress, calcium overload, inflammation, and apoptosis. The NRG1/ErbB4 signaling pathway has been implicated in modulating oxidative stress responses in the heart, potentially reducing cellular damage caused by free radicals.

View Article and Find Full Text PDF

Background: Patients with end-stage heart failure and chronic kidney disease requiring dual-organ transplantation (DOT) face significant challenges in utilizing durable mechanical circulatory support due to the risks associated with renal replacement therapies (RRTs) and multi-organ failure. Given the limited options available for long-term support in this patient population, there remains a critical need for alternative strategies to optimize end-organ function and bridge patients safely to transplant. With prolonged waitlist times for DOT, we present our experience with the Impella 5.

View Article and Find Full Text PDF

Durable Long-Term Outcomes After Early Transcatheter Arterialization of the Deep Veins.

JACC Case Rep

September 2025

University Hospitals Harrington Heart & Vascular Institute, Cleveland, Ohio, USA. Electronic address:

Background: Up to 20% of patients with chronic limb-threatening ischemia (CLTI) are not eligible for conventional revascularization options despite having severe symptoms of nonhealing ulcers and gangrene. Transcatheter arterialization of the deep veins (TADV) has shown promising results in this challenging subset of patients.

Case Summary: We present the long-term outcomes of 4 patients with no-option CLTI who were at risk of major below-the-knee amputation and were treated with TADV with the LimFlow System (Inari Medical).

View Article and Find Full Text PDF